Immune-based drug beats standard neuroblastoma therapy in study

05/14/2009 | Forbes

An immune-based treatment called chimeric anti-GD2 antibody ch14.18 outperformed standard retinoic acid therapy in improving overall survival of patients with high-risk neuroblastoma, a cancer of the nervous system that affects mostly children, according to a late-stage study. Researchers hope the findings will lead to more availability of the treatment for children with neuroblastoma.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC